Waterfall Scientific Lands $54.5M for mRNA Manufacturing Innovation

Waterfall Scientific is set to revolutionize mRNA manufacturing with a substantial award of up to $54.5 million from the Advanced Research Projects Agency for Health (ARPA-H). This significant funding will empower a six-company consortium, led by Waterfall Scientific, to develop a groundbreaking continuous-flow platform for the rapid production and characterization of mRNA therapeutics and vaccines. The initiative, dubbed ESCALATOR, falls under ARPA-H's GIVE program, aiming to accelerate genetic medicine development.

The consortium's ambitious goal is to create an integrated, end-to-end system that moves beyond traditional, time-consuming batch processes. By combining advanced technologies such as enzymatic DNA synthesis from Ansa Biotechnologies, automated fluid handling by Volta Labs, and lipid nanoparticle formulation from Polymorphic Biosciences, the platform promises to drastically reduce production timelines. This shift from weeks to mere days for mRNA therapeutic lead times could be a game-changer for areas like pandemic preparedness, personalized cancer treatments, and addressing rare genetic disorders.

Waterfall Scientific, a Massachusetts-based firm with roots in the University of Massachusetts Amherst, will orchestrate the project. Its proprietary DuoTether continuous-flow system is central to enhancing mRNA synthesis purity and efficiency. The collaboration also includes Tensentric, responsible for custom hardware design and commercial prototyping, and Ginkgo Bioworks, contributing expertise in system integration and computational optimization. This collective expertise aims to streamline the entire manufacturing workflow, from initial synthesis to final product characterization.

This substantial investment from ARPA-H underscores the growing strategic importance of domestic biomanufacturing capabilities. The push for continuous-flow processes addresses critical bottlenecks and high costs associated with current mRNA production methods, which have been highlighted by the rapid scale-up required during recent global health crises. The ESCALATOR project's success could significantly lower unit costs and reduce the physical footprint of manufacturing facilities, making advanced therapies more accessible.

The implications for the biotechnology sector are profound. A more agile and cost-effective mRNA manufacturing infrastructure could unlock new therapeutic avenues and accelerate the development of personalized medicines. The ability to produce high-purity mRNA on demand, as envisioned by the consortium, positions the United States at the forefront of next-generation biopharmaceutical production, fostering innovation and enhancing national health security.

Inna Shcherbakova, Ph.D., Co-Founder and CEO of Waterfall Scientific, emphasized the award as a pivotal moment, stating, “This award strongly endorses our continuous-flow paradigm. By uniting best-in-class capabilities across enzymatic DNA synthesis, formulation, microfluidics, automated hardware, and high-throughput analytics, we are establishing a scalable platform that will redefine how nucleic acid therapies are manufactured globally.”

Echoing this sentiment, Melissa J. Moore, Ph.D., Co-Founder of Waterfall Scientific, added, “This investment provides a truly exciting opportunity to move our promising technologies from concept to meaningful impact. We look forward to working with ARPA-H and our collaborators to deliver results for patients, providers, and communities.” The combined efforts of these leading organizations are expected to yield a robust and scalable solution for the future of genetic medicine manufacturing.